In addition to studies focusing on HR-MDS, the program includes a doublet or triplet sabatolimab study for patients with low-risk MDS, which is in the recruiting stage (NCT04810611), for patients with AML that makes them unfit for intensive chemotherapy (STIMULUS-AML1, NCT04150029), and for AML posttransplant patients with measurable residual disease, which is also in the recruiting stage (STIMULUS-AML2, NCT04623216) [172]. This evidence concerns the gene RUNX1 and myelodysplastic syndrome.